A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome

Transfusion Medicine Reviews

Volumn 28, Issue 4, 2014, Pages 187-197

  Tsai, Han Mou ^a,b  

^a IMAH Hematology   (United States)

^b E DA HOSPITAL   (Taiwan)

Author keywords

Atypical hemolytic uremic syndrome; Complement system; Microangiopathic hemolytic anemia; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

ECULIZUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; COMPLEMENT; MONOCLONAL ANTIBODY; RITUXIMAB;

AUTOIMMUNE DISEASE; COMPLEMENT SYSTEM; DIFFERENTIAL DIAGNOSIS; ENDOTHELIUM INJURY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LUPUS VULGARIS; MOLECULAR PATHOLOGY; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PREGNANCY; REVIEW; SOLID ORGAN TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; TREATMENT RESPONSE; ADULT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMORBIDITY; CYTOLOGY; GENE DELETION; GENETICS; HEMATOPOIETIC STEM CELL; MUTATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SPLENECTOMY; TREATMENT OUTCOME;

ADAM PROTEINS; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMORBIDITY; COMPLEMENT SYSTEM PROTEINS; DIAGNOSIS, DIFFERENTIAL; GENE DELETION; HEMATOPOIETIC STEM CELLS; HUMANS; MUTATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RITUXIMAB; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84911405240     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2014.08.004     Document Type: Review

References (54)

1. Kaplan B.S., Chesney R.W., Drummond K.N. Hemolytic uremic syndrome in families. N Engl J Med 1975, 292:1090-1093.
2. Fitzpatrick M.M., Dillon M.J., Barratt T.M., Trompeter R.S. Atypical hemolytic uremic syndrome. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura 1992, 163-178. Marcel Dekker, Inc. B.S. Kaplan, R.S. Trompeter, J.L. Moake (Eds.).
3. George J.N. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010, 116:4060-4069.
4. Tsai H.M. Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: an update. Hematol Oncol Clin North Am 2013, 27:565-584.
5. Fremeaux-Bacchi V., Fakhouri F., Garnier A., Bienaime F., Dragon-Durey M.A., Ngo S., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554-562.
6. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
7. Tsai H.M., Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 2003, 70:183-185.
8. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339:1585-1594.
9. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413:488-494.
10. Furlan M., Lammle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin Haematol 1998, 11:509-514.
11. Cochran J.B., Panzarino V.M., Maes L.Y., Tecklenburg F.W. Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia. Pediatr Nephrol 2004, 19:317-321.
12. Waters A.M., Kerecuk L., Luk D., Haq M.R., Fitzpatrick M.M., Gilbert R.D., et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience. J Pediatr 2007, 151:140-144.
13. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
14. Izzedine H., Massard C., Spano J.P., Goldwasser F., Khayat D., Soria J.C. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010, 46:439-448.
15. Hayman S.R., Leung N., Grande J.P., Garovic V.D. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012, 14:285-294.
16. Veron D., Villegas G., Aggarwal P.K., Bertuccio C., Jimenez J., Velazquez H., et al. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoS One 2012, 7:e40589. 10.1371/journal.pone.0040589.
17. Lemaire M., Frémeaux-Bacchi V., Schaefer F., Choi M., Tang W.H., Le Quintrec M., et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013, 45:531-536.
18. Ozaltin F., Li B., Rauhauser A., An S.W., Soylemezoglu O., Gonul I.I., et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013, 24:377-384.
19. Brunelli S.M., Meyers K.E., Guttenberg M., Kaplan P., Kaplan B.S. Cobalamin C deficiency complicated by an atypical glomerulopathy. Pediatr Nephrol 2002, 17:800-803.
20. Cornec-Le G.E., Delmas Y., De P.L., Doucet L., Ogier H., Benoist J.F., et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014, 63:119-123.
21. Bu F., Maga T., Meyer N.C., Wang K., Thomas C.P., Nester C.M., et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014, 25:55-64.
22. Klammt J., Kobelt L., Aktas D., Durak I., Gokbuget A., Hughes Q., et al. Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity. Thromb Haemost 2011, 105:454-460.
23. Mehta R., Shapiro A.D. Plasminogen deficiency. Haemophilia 2008, 14:1261-1268.
24. Zipfel P.F., Edey M., Heinen S., Jozsi M., Richter H., Misselwitz J., et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007, 3:e41. 10.1371/journal.pgen.0030041.
25. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
26. Maga T.K., Nishimura C.J., Weaver A.E., Frees K.L., Smith R.J. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010, 31:E1445-E1460.
27. Bienaime F., Dragon-Durey M.A., Regnier C.H., Nilsson S.C., Kwan W.H., Blouin J., et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010, 77:339-349.
28. Fremeaux-Bacchi V., Kemp E.J., Goodship J.A., Dragon-Durey M.A., Strain L., Loirat C., et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005, 42:852-856.
29. Esparza-Gordillo J., Goicoechea de J.E., Buil A., Carreras B.L., Lopez-Trascasa M., Sanchez-Corral P., et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005, 14:703-712.
30. Esparza-Gordillo J., Jorge E.G., Garrido C.A., Carreras L., Lopez-Trascasa M., Sanchez-Corral P., et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006, 43:1769-1775.
31. Ermini L., Goodship T.H., Strain L., Weale M.E., Sacks S.H., Cordell H.J., et al. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol 2012, 49:640-648.
32. Heurich M., Martinez-Barricarte R., Francis N.J., Roberts D.L., Rodriguez de C.S., Morgan B.P., et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 2011, 108:8761-8766.
33. Jozsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
34. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379-387.
35. Dragon-Durey M.A., Blanc C., Marliot F., Loirat C., Blouin J., Sautes-Fridman C., et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009, 46:447-450.
36. Auda G., Holme E.R., Davidson J.E., Zoma A., Veitch J., Whaley K. Measurement of complement activation products in patients with chronic rheumatic diseases. Rheumatol Int 1990, 10:185-189.
37. Porcel J.M., Ordi J., Castro-Salomo A., Vilardell M., Rodrigo M.J., Gene T., et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 1995, 74:283-288.
38. Oleesky D.A., Daniels R.H., Williams B.D., Amos N., Morgan B.P. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions. Clin Exp Immunol 1991, 84:250-255.
39. Jodele S., Licht C., Goebel J., Dixon B.P., Zhang K., Sivakumaran T.A., et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013, 122:2003-2007.
40. Iacopino P., Pucci G., Arcese W., Bosi A., Falda M., Locatelli F., et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999, 24:47-51.
41. Daly A.S., Hasegawa W.S., Lipton J.H., Messner H.A., Kiss T.L. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci 2002, 27:3-12.
42. Hahn T., Alam A.R., Lawrence D., Ford L., Baer M.R., Bambach B., et al. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion. Transplantation 2004, 78:1515-1522.
43. Denny K.J., Woodruff T.M., Taylor S.M., Callaway L.K. Complement in pregnancy: a delicate balance. Am J Reprod Immunol 2013, 69:3-11.
44. Haeger M., Unander M., Bengtsson A. Complement activation in relation to development of preeclampsia. Obstet Gynecol 1991, 78:46-49.
45. Haeger M., Unander M., Bengtsson A. Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1990, 76:698-702.
46. Salmon J.E., Heuser C., Triebwasser M., Liszewski M.K., Kavanagh D., Roumenina L., et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011, 8:e1001013. 10.1371/journal.pmed.1001013.
47. Scully M., Thomas M., Underwood M., Watson H., Langley K., Camilleri R.S., et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014, 124:211-219.
48. Noris M., Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013, 22:704-712.
49. Tsai H.-M. Acquired thrombotic thrombocytopenic purpura. ADAMTS13: biology and disease, chapter 7 2014, Springer, [in press]. G. Rodgers (Ed.).
50. Noris M., Remuzzi G. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol 2010, 30:395-408.
51. Tsai H.-M. Thrombotic thrombocytopenic purpura, hemolytic uremic syndrome and related disorders. Wintrobe's clinical hematology, 13/e, Chapter 48 2013, Lippincott Williams & Wilkins. J.P. Greer, J. Foerster, G.M. Rodgers, F. Paraskevas, B. Glader, D.A. Arber, R.T. Means (Eds.).
52. Hirata S., Okamoto H., Ohta S., Kobashigawa T., Uesato M., Kawaguchi Y., et al. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease. Rheumatology (Oxford) 2006, 45:1046-1047.
53. Chapin J., Weksler B., Magro C., Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012, 157:772-774.
54. Tsai E., Chapin J., Laurence J.C., Tsai H.M. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 2013, 162:558-559.